vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $140.7M, roughly 1.3× Purple Innovation, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -2.3%, a 15.6% gap on every dollar of revenue. On growth, Purple Innovation, Inc. posted the faster year-over-year revenue change (9.1% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-7.8M). Over the past eight quarters, Purple Innovation, Inc.'s revenue compounded faster (8.3% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
AMPH vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $140.7M |
| Net Profit | $24.4M | $-3.2M |
| Gross Margin | 46.8% | 41.9% |
| Operating Margin | 19.4% | -1.6% |
| Net Margin | 13.3% | -2.3% |
| Revenue YoY | -1.8% | 9.1% |
| Net Profit YoY | -35.7% | 62.1% |
| EPS (diluted) | $0.51 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $140.7M | ||
| Q3 25 | $191.8M | $118.8M | ||
| Q2 25 | $174.4M | $105.1M | ||
| Q1 25 | $170.5M | $104.2M | ||
| Q4 24 | $186.5M | $129.0M | ||
| Q3 24 | $191.2M | $118.6M | ||
| Q2 24 | $182.4M | $120.3M | ||
| Q1 24 | $171.8M | $120.0M |
| Q4 25 | $24.4M | $-3.2M | ||
| Q3 25 | $17.4M | $-11.7M | ||
| Q2 25 | $31.0M | $-17.3M | ||
| Q1 25 | $25.3M | $-19.1M | ||
| Q4 24 | $38.0M | $-8.5M | ||
| Q3 24 | $40.4M | $-39.2M | ||
| Q2 24 | $37.9M | $27.0K | ||
| Q1 24 | $43.2M | $-50.2M |
| Q4 25 | 46.8% | 41.9% | ||
| Q3 25 | 51.4% | 42.8% | ||
| Q2 25 | 49.6% | 35.9% | ||
| Q1 25 | 50.0% | 39.4% | ||
| Q4 24 | 46.5% | 42.9% | ||
| Q3 24 | 53.3% | 29.7% | ||
| Q2 24 | 52.2% | 40.7% | ||
| Q1 24 | 52.4% | 34.8% |
| Q4 25 | 19.4% | -1.6% | ||
| Q3 25 | 13.2% | -10.2% | ||
| Q2 25 | 24.2% | -13.5% | ||
| Q1 25 | 21.9% | -13.9% | ||
| Q4 24 | 24.2% | -6.0% | ||
| Q3 24 | 29.8% | -39.5% | ||
| Q2 24 | 30.3% | -12.1% | ||
| Q1 24 | 27.9% | -19.3% |
| Q4 25 | 13.3% | -2.3% | ||
| Q3 25 | 9.0% | -9.9% | ||
| Q2 25 | 17.8% | -16.5% | ||
| Q1 25 | 14.8% | -18.4% | ||
| Q4 24 | 20.4% | -6.6% | ||
| Q3 24 | 21.1% | -33.1% | ||
| Q2 24 | 20.8% | 0.0% | ||
| Q1 24 | 25.1% | -41.8% |
| Q4 25 | $0.51 | $0.03 | ||
| Q3 25 | $0.37 | $0.11 | ||
| Q2 25 | $0.64 | $0.16 | ||
| Q1 25 | $0.51 | $0.18 | ||
| Q4 24 | $0.74 | $0.08 | ||
| Q3 24 | $0.78 | $0.36 | ||
| Q2 24 | $0.73 | $0.00 | ||
| Q1 24 | $0.81 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $24.3M |
| Total DebtLower is stronger | $608.7M | $126.7M |
| Stockholders' EquityBook value | $788.8M | $-29.7M |
| Total Assets | $1.6B | $296.3M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $24.3M | ||
| Q3 25 | $276.2M | $32.4M | ||
| Q2 25 | $231.8M | $34.2M | ||
| Q1 25 | $236.9M | $21.6M | ||
| Q4 24 | $221.6M | $29.0M | ||
| Q3 24 | $250.5M | $23.4M | ||
| Q2 24 | $217.8M | $23.4M | ||
| Q1 24 | $289.6M | $34.5M |
| Q4 25 | $608.7M | $126.7M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $70.7M | ||
| Q3 24 | $596.4M | $50.8M | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-29.7M | ||
| Q3 25 | $776.7M | $-26.9M | ||
| Q2 25 | $757.5M | $-15.6M | ||
| Q1 25 | $751.3M | $1.3M | ||
| Q4 24 | $732.3M | $20.2M | ||
| Q3 24 | $727.7M | $28.0M | ||
| Q2 24 | $713.3M | $66.4M | ||
| Q1 24 | $672.4M | $65.5M |
| Q4 25 | $1.6B | $296.3M | ||
| Q3 25 | $1.7B | $302.1M | ||
| Q2 25 | $1.6B | $303.8M | ||
| Q1 25 | $1.6B | $293.8M | ||
| Q4 24 | $1.6B | $307.8M | ||
| Q3 24 | $1.5B | $309.3M | ||
| Q2 24 | $1.5B | $362.1M | ||
| Q1 24 | $1.6B | $382.1M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 3.50× | ||
| Q3 24 | 0.82× | 1.82× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-5.8M |
| Free Cash FlowOCF − Capex | $24.6M | $-7.8M |
| FCF MarginFCF / Revenue | 13.4% | -5.5% |
| Capex IntensityCapex / Revenue | 4.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-5.8M | ||
| Q3 25 | $52.6M | $-968.0K | ||
| Q2 25 | $35.6M | $-4.0M | ||
| Q1 25 | $35.1M | $-23.1M | ||
| Q4 24 | $29.0M | $6.8M | ||
| Q3 24 | $60.0M | $1.1M | ||
| Q2 24 | $69.1M | $-8.9M | ||
| Q1 24 | $55.3M | $-16.8M |
| Q4 25 | $24.6M | $-7.8M | ||
| Q3 25 | $47.2M | $-1.8M | ||
| Q2 25 | $25.0M | $-7.0M | ||
| Q1 25 | $24.4M | $-25.3M | ||
| Q4 24 | $16.6M | $5.7M | ||
| Q3 24 | $46.2M | $101.0K | ||
| Q2 24 | $63.1M | $-11.0M | ||
| Q1 24 | $46.5M | $-19.9M |
| Q4 25 | 13.4% | -5.5% | ||
| Q3 25 | 24.6% | -1.5% | ||
| Q2 25 | 14.3% | -6.6% | ||
| Q1 25 | 14.3% | -24.3% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 0.1% | ||
| Q2 24 | 34.6% | -9.2% | ||
| Q1 24 | 27.1% | -16.5% |
| Q4 25 | 4.5% | 1.4% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 2.8% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 0.8% | ||
| Q3 24 | 7.2% | 0.9% | ||
| Q2 24 | 3.3% | 1.7% | ||
| Q1 24 | 5.1% | 2.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | -330.22× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
